Cancer Medicine最新文献

{"title":"Direct Oral Anticoagulants Are Comparable to Low Molecular Weight Heparin at Sustaining the Circulating Extracellular Vesicle and Inflammatory Profiles of Cancer Associated Thrombosis Patients: An Observational Pilot Study","authors":"H. Macleod,&nbsp;N. Copty,&nbsp;D. Doherty,&nbsp;L. Weiss,&nbsp;E. Fouhy,&nbsp;R. Power,&nbsp;N. Ryan,&nbsp;K. Saeed,&nbsp;E. ORourke,&nbsp;R. Faryal,&nbsp;S. Kelliher,&nbsp;B. Kevane,&nbsp;F. Ní Áinle,&nbsp;P. B. Maguire","doi":"10.1002/cam4.70920","DOIUrl":"https://doi.org/10.1002/cam4.70920","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Cancer patients face a 4 to 7-fold higher risk of developing thrombotic events compared to individuals without cancer. This elevated risk is driven by the underlying tumour biology and the effects of cancer treatments, significantly increasing the mortality rates of these patients. While low molecular weight heparin (LMWH) is the gold standard anticoagulation, direct oral anticoagulants (DOACs) are emerging as effective alternatives. Recent clinical evidence indicates reduced recurrent VTE upon DOAC treatment compared to LMWH; however, there is limited understanding of the underlying mechanistic pathways. Of interest, extracellular vesicles (EVs), released from a multitude of cells including platelets and tumour cells, are known as potent intercellular communication mediators, capable of progressing coagulation, thrombosis, as well as tumour growth and metastasis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We characterised the extracellular vesicles and inflammatory markers associated with hypercoagulability and thrombosis in cancer-associated thrombosis (CAT) patients, comparing those treated for 8 weeks with DOACs to those receiving LMWH. This pilot observational study recruited 28 CAT patients (21 baseline, 13 treated with DOACs, 8 treated with LMWH; 14 paired) and quantified their circulating, platelet-derived, and endothelial-derived EVs using Nanoparticle Tracking Analysis and flow cytometry. Proteomics was performed on the EV cargo and patient plasma, quantifying the inflammatory profiles of the patients under both treatment arms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results and Discussion</h3>\u0000 \u0000 <p>We demonstrated that DOAC treatment maintained hypercoagulable and prothrombotic EV profiles similar to LMWH treatment, showing a remarkably stable EV cargo proteome. Inflammatory profiles were also comparable between treatment arms, with a trend toward a DOAC-mediated reduction of circulating cytokines, highlighting potential anti-inflammatory effects.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This pilot study demonstrates that DOACs sustain the circulating EV and inflammatory profiles to the same extent as LMWH, supporting this clinical shift in anticoagulant treatment in the cancer setting.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 9","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70920","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143880075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Integrin Glycovariants as Biomarkers of Metastasis, Invasion, and Therapy Stratification in Head and Neck Squamous Cell Carcinoma","authors":"Erica Routila,&nbsp;Sadie Salminen,&nbsp;Randa Mahran,&nbsp;Mervi Toriseva,&nbsp;Heikki Irjala,&nbsp;Eeva Haapio,&nbsp;Eero Kytö,&nbsp;Sami Ventelä,&nbsp;Kim Pettersson,&nbsp;Johannes Routila,&nbsp;Kamlesh Gidwani,&nbsp;Janne Leivo","doi":"10.1002/cam4.70717","DOIUrl":"https://doi.org/10.1002/cam4.70717","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Integrin glycosylation is one mechanism regulating the invasion and metastasis of malignant tumors. Little information exists about integrin glycosylation in head and neck squamous cell carcinoma (HNSCC). In this study, we evaluated the glycosylation of integrins in HNSCC tumor and serum samples.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Intraoperative fresh tumor and normal tissue samples and blood samples were collected from HNSCC patients (<i>N</i> = 24). Lectin-bioaffinity assays using six nanoparticle-bound lectins were used to evaluate the glycosylation of integrins ITGA2, ITGA3, ITGA5, ITGA6, ITGB1, and ITGB4. Associations with metastasis, therapy response, and clinical factors were analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Glycosylation profiles of the integrins were relatively similar. High intratumoral ITGB1–WFL results were associated with high T class, whereas none of the integrin glycovariant assays provided significant resolution in the detection of nodal metastasis. While the serum integrin glycovariant levels were low overall, serum ITGA2–UEA offered significant resolution in both radiotherapy response prediction and cancer recurrence prognostication.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We demonstrate that while integrin glycovariants are abundant in HNSCC tumors and ITGB1-WFL was associated with invasiveness, integrin glycovariants do not directly correlate with metastatic behavior. Further, serum ITGA2–UEA appeared as a potential radioresponse biomarker.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 9","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70717","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143877780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality for All: Clinical Trial Enrollment and End-of-Life Care in Solid and Hematologic Malignancies","authors":"Melissa R. Rosen,&nbsp;Tracy Truong,&nbsp;Catherine Gervais,&nbsp;Thomas W. LeBlanc,&nbsp;Laura J. Havrilesky,&nbsp;Brittany A. Davidson","doi":"10.1002/cam4.70775","DOIUrl":"https://doi.org/10.1002/cam4.70775","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Patients with incurable cancer deserve quality end-of-life (EOL) care. Despite established EOL quality metrics, many patients receive aggressive EOL care with limited goals of care (GOC) documentation. Concurrently, clinical trials are critical for advancing cancer care. We aim to identify associations between trial enrollment in the last year of life (YOL) and EOL quality metrics for adults with cancer to identify opportunities to advance goal-concordant care.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This is a retrospective review of adult patients with cancer at a single academic institution who died between January 2018 and October 2022. Outcomes included: initiation of a new anticancer therapy, intensive care unit (ICU) admission, hospitalization, or emergency department (ED) encounter in the last 30 days of life (DOL), reception of anti-cancer treatment in the last 14 DOL, referral to hospice, referral to palliative care, and GOC documentation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 9817 patients, 577 (5.9%) enrolled in clinical trials in the last YOL. Patients enrolled in trials were more likely to initiate new anticancer treatments in the last 30 DOL (<i>p</i> = &lt; 0.001), less likely to have a palliative care referral (<i>p</i> = &lt; 0.001) or GOC documentation (<i>p</i> = &lt; 0.001), but were less likely to have an ED encounter in the last 30 DOL (<i>p</i> = 0.04) or die in an acute care setting (<i>p</i> = 0.015).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Enrollment in clinical trials in the last YOL was associated with metrics of aggressive EOL care, with low rates of GOC documentation to determine if this care is goal-concordant. Low rates of palliative care and hospice engagement across the study population suggest opportunities for improvement for all patients, regardless of trial enrollment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 9","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70775","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143877798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis and Treatment of Primary Tracheobronchial Tumors","authors":"Chen Shu,&nbsp;Yu-jian Liu,&nbsp;Kai-fu Zheng,&nbsp;Xi-yang Tang,&nbsp;Meng-chao Li,&nbsp;Yang Shen,&nbsp;Yu-long Zhou,&nbsp;Wei-guang Du,&nbsp;Nan Ma,&nbsp;Jin-bo Zhao","doi":"10.1002/cam4.70893","DOIUrl":"https://doi.org/10.1002/cam4.70893","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Primary tracheobronchial tumors (PTBTs) are rare but life-threatening, accounting for approximately 0.2% of all respiratory neoplasms. Owing to their nonspecific clinical symptoms, PTBTs are often initially misdiagnosed as bronchial asthma or bronchitis in the early stages. In addition, standardized treatments for PTBTs are currently lacking.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aimed to provide a comprehensive review of this diagnostic challenge and treatment modalities of PTBTs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Drawing on the latest literature and clinical guidelines, we carried out a comprehensive and systematic analysis of PTBTs, focusing on diagnostic modalities, and evidence-based treatment options.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results and Conclusions</h3>\u0000 \u0000 <p>Primary diagnostic methods for PTBTs include pulmonary function tests, chest radiography, computed tomography, and fiberoptic bronchoscopy. Computed tomography, and fiberoptic bronchoscopy may be the most valuable diagnostic tools for patients with PTBTs or those highly suspected of having PTBTs. Currently, there are no consensus guidelines for PTBTs, and surgery is the most effective method for treating PTBTs if the patients have indications for surgery. In addition, radiotherapy, chemotherapy and interventional therapy may be useful complementary treatments for inoperable patients. Immunotherapy may be a significant management strategy for PTBTs in the future. Further researches should concentrate on both the early identification and enhanced therapeutic management of these tumors to improve survival and diminish morbidity and mortality rates by investigating the optimal design of systematic therapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 9","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70893","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143880088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Network-Based Integrative Analysis to Identify Key Genes and Corresponding Reporter Biomolecules for Triple-Negative Breast Cancer","authors":"Pooja Singh,&nbsp;Rupesh Chaturvedi,&nbsp;Pallavi Somvanshi","doi":"10.1002/cam4.70674","DOIUrl":"https://doi.org/10.1002/cam4.70674","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The malignant neoplasm of the TNBC is the leading cause of death among Indian women. Recent studies identified the global burden of TNBC affecting approximately more than 40 percent of all BC cases in women worldwide. The absence of expression of receptors such as ER, PR, and HER2 characterizes TNBC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Due to the lack of specific targets, standard treatment options for TNBC are limited. This integrative study aims to identify key genes and provide insights into the underlying molecular mechanisms of TNBC, which can potentially lead to the development of more effective therapeutic strategies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Material and Methodology</h3>\u0000 \u0000 <p>This study integrates PPI and WGCNA analysis of TNBC-related datasets (GSE52194 and GSE58135) to identify key genes. Subsequently, downstream analysis is conducted to explore potential therapeutic targets for TNBC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The present study renders the potential 13 key genes (PLCG2, CXCL10, CDK1, STAT1, IL6, PLK1, CCNB1, AURKA, NDC80, EGFR, 1L1B, FN1, BUB1B), along with their associated 6 TFs and 20 miRNAs, as reporter biomolecules around which the most significant changes occur. There were some miRNAs hsa-mir-449b-5p, hsa-let-7b-5p, hsa-mir-26a-5p, hsa-mir-155-5p, hsa-mir-24-3p, hsa-mir-212-3p, hsa-mir-21-5p, hsa-mir-210-3p and hsa-mir-20a-5p whose association with other cancers and other BC subtypes have been reported but their association with TNBC need to be explored. Further, enrichment and cumulative survival analysis support the disease association of identified key genes with TNBC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This integrative analysis could be regarded for experimental inspection as it provides the platform for future researchers in drug designing and biomarker discovery for TNBC diagnosis and treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 9","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70674","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143877799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of the Biochemical Recurrence Prediction Ability and Progression Correlation of Peroxiredoxins Family in Prostate Cancer Based on Integrating Single-Cell RNA-Seq and Bulk RNA-Seq Cohorts","authors":"Shan Tang,&nbsp;Jinchuang Li,&nbsp;Weicheng Tian,&nbsp;Yuanfa Feng,&nbsp;Yulin Deng,&nbsp;Zeheng Tan,&nbsp;Zhaodong Han,&nbsp;Huichan He,&nbsp;Yongding Wu,&nbsp;Chuyang Huang,&nbsp;Keping Ning,&nbsp;Feng Liu,&nbsp;Hongwei Luo,&nbsp;Shanghua Cai,&nbsp;Jianheng Ye,&nbsp;Weide Zhong","doi":"10.1002/cam4.70855","DOIUrl":"https://doi.org/10.1002/cam4.70855","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The peroxiredoxins (PRDXs) family plays a crucial role in balancing reactive oxygen species (ROS) levels in tumor cells. However, its potential role in prognosis and therapy response of prostate cancer (PCa) remains unknown.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this study, we utilized 2 public single-cell RNA datasets and 8 bulk-RNA datasets to investigate the clinical value of six PRDXs family members in PCa. Expression comparison, biochemical recurrence analysis, and therapy response analysis were measured. Pathway enrichments were utilized to predict the potential down-stream pathway it may involve. In vitro experiments were used to validate the function of PRDX5 in the progression of castration-resistant prostate cancer (CRPC) cell lines.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Result</h3>\u0000 \u0000 <p>Among the PRDXs family, PRDX5 was most related to the advancement of prostate cancer. A nomogram integrating the expression of PRDX5 with clinical features was developed to better predict clinical outcomes in PCa patients compared to 30 published signatures. Immunohistochemistry was used to verify that PRDX5 expression was higher in advanced levels of PCa tissue. Gene Set Enrichment Analysis (GSEA) and pathway predictive analysis revealed that the PRDX5 related genes were mainly relevant to ROS Pathway, Mitochondria-related functions, cellular respiration, and oxidative phosphorylation. In vitro cell proliferation assays, ROS determination assay, and apoptosis assay together revealed that depletion of PRDX5 induces apoptosis via ROS accumulation in CRPC cells. Moreover, the expression of PRDX5 in CRPC cells also affects the sensitivity to the ARSI therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study offers new evidence for determining that the expression of PRDX5 is associated with advanced tumor grade, poor prognosis, and suboptimal response to multiple therapies in PCa within the PRDXs family. Last but not least, our study provides new insights into precision medicine in PCa and provides a reference for further research on PRDX5.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 9","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70855","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143875488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcome of Patients With Cancer-Associated Pulmonary Embolism: Results From the Regional Pulmonary Embolism Registry","authors":"Sonja Salinger,&nbsp;Aleksandra Kozic,&nbsp;Boris Dzudovic,&nbsp;Bojana Subotic,&nbsp;Jovan Matijasevic,&nbsp;Marija Benic,&nbsp;Vladimir Miloradovic,&nbsp;Ema Jevtic,&nbsp;Tamara Kovacevic-Preradovic,&nbsp;Ljiljana Kos,&nbsp;Nebojsa Bulatovic,&nbsp;Bjanka Bozovic,&nbsp;Irena Mitevska,&nbsp;Marijan Bosevski,&nbsp;Ana Kovacevic-Kuzmanovic,&nbsp;Milos Svircev,&nbsp;Aleksandar Neskovic,&nbsp;Bojan Mitrovic,&nbsp;Srdjan Kafedzic,&nbsp;Slobodan Obradovic","doi":"10.1002/cam4.70886","DOIUrl":"https://doi.org/10.1002/cam4.70886","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Newly or already diagnosed cancer might significantly influence the clinical presentation, outcome, and therapy of acute pulmonary embolism (PE).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Out of 1745 patients with acute PE, 66 patients were diagnosed with cancer during an initial hospitalization due to acute PE (where PE was the first clinical manifestation of cancer), 165 patients had known cancer treated in the last 6 months, and 1514 patients had acute PE without known or suspected cancer. The primary end-point of the present study was all-cause hospital death. The secondary end-points were the proportion of patients treated with thrombolysis and who had severe disease, and the ocurrence of major or clinically relevant nonmajor bleeding.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patients with PE as the first presentation of cancer had the highest hospital mortality rate compared to the other two groups (HR for the mortality rate in patients without cancer as a reference, adjusted to four-stratum mortality risk, and Charlson's comorbidity index was 3.440; 95% confidence interval (CI), 1.795–6.591; <i>p</i> &lt; 0.001). Patients with known cancer before PE had a significantly lower chance of being treated with thrombolysis than patients without cancer (OR, 0.523; 95% CI, 0.339–0.807; <i>p</i> = 0.003); additionally, this difference was attenuated but remained when the OR was adjusted to age (OR, 0.542; 95% CI, 0.351–0.838; <i>p</i> = 0.006). Patients with known cancer had a higher frequency of high-risk PE compared with patients without cancer (18.2% vs. 12.8%; <i>p</i> &lt; 0.001). Patients with PE as the first manifestation of cancer had a higher frequency of intermediate-high-risk PE than those without (36.4% vs. 30.9%; <i>p</i> &lt; 0.001). There was no significant difference in bleeding during hospitalization between groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Patients with cancer had a more severe presentation of acute PE than patients without. Furthermore, patients with PE as the first manifestation of cancer had the highest hospital mortality rate, and patients with known cancer were least likely to be treated with thrombolysis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 9","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70886","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Associations Between Gallstone Disease and Pan-Cancer Incidence Risk Based on Over 13 Million Participants","authors":"Wenqian Yu,&nbsp;Jin Zhou,&nbsp;Jing Luo,&nbsp;Jing Xia,&nbsp;Shiyi Li,&nbsp;Linjun Xie,&nbsp;YaZhou He,&nbsp;Hongyu Li,&nbsp;Guoheng Jiang,&nbsp;Xin Chen,&nbsp;Xuan Bai,&nbsp;Min Mao,&nbsp;Xin Wang","doi":"10.1002/cam4.70857","DOIUrl":"https://doi.org/10.1002/cam4.70857","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Increasing evidence connects gallstone disease (GSD) to all types of cancer incidence; however, the results were inconsistent. The present study aimed to evaluate whether and to what extent these associations exist comprehensively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We systematically searched published longitudinal studies indexed in PubMed and Embase database from dates of inception to March 31, 2020. We pooled the effect of GSD on all-cause cancer incidence. Moreover, we further employed stratified analysis concerning sex, geographic background, surgery status, and follow-up period. Trial sequential analysis (TSA) was applied to decide whether the included sample size was sufficient for evaluating these associations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Fifty-one studies incorporating over 13 million participants were eligible for analysis in this study. GSD pose an increased risk of all-cause cancer risk (pooled RR = 1.43; 95% CI: 1.33–1.54) compared with the healthy controls, especially hematologic malignancy (pooled RR = 1.14; 95% CI: 1.05–1.25), gastrointestinal cancers (pooled RR = 1.28; 95% CI: 1.15–1.41), liver, pancreas, and biliary tract cancer (pooled RR = 1.84; 95% CI: 1.62–2.10), and kidney cancer (pooled RR = 1.19; 95% CI: 1.03–1.37). These associations are not markedly changed after stratification by different subgroups. Moreover, the TSA confirmed the sample size was sufficient to draw these conclusive conclusions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The present meta-analysis with sufficient evidence indicates GSD increases the risk for all causes of cancer incidence. The evidence may warrant GSD patients to perform screening and prophylactic treatment for the prevention of these complications. The indication for cholecystectomy should be determined through a comprehensive evaluation of the patient's clinical presentation, with a thorough assessment of the potential therapeutic benefits and surgical risks.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 9","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70857","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of Pre-Treatment Diffusion Kurtosis Imaging for Progression-Free Survival Prediction in Advanced Nasopharyngeal Carcinoma","authors":"Wang Ren,&nbsp;Xiang Zheng,&nbsp;Shizhong Wu,&nbsp;Caixia Wu,&nbsp;Dechun Zheng","doi":"10.1002/cam4.70883","DOIUrl":"https://doi.org/10.1002/cam4.70883","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>This study aimed to evaluate the value of diffusion kurtosis imaging (DKI) for prognostic value for long-term PFS in nasopharyngeal carcinoma (NPC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cohort of 295 NPC patients underwent pretreatment 3.0T MRI with DKI to derive mean kurtosis (MK), mean diffusion (MD), and apparent diffusion coefficient (ADC). Clinical parameters (Tumor stage, EBV-DNA, neoadjuvant chemotherapy regimens) were recorded. Follow-up extended to December 2023. Statistical analyses (R software v4.3.0) included univariate/multivariate Cox regression and Kaplan–Meier survival analysis. A prognostic nomogram integrating key predictors was developed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Median 10-year follow-up revealed 2-, 5-, and 10-year PFS rates of 89%, 79%, and 74%, respectively. Univariate Cox regression analysis demonstrated that T stage, Clinical Stages, NAC regimens, ADC_Group, MK_Group, and MD_Group were significant prognostic factors for PFS in NPC (<i>p</i> &lt; 0.05). Multivariate analysis identified Clinical Stage (HR = 2.230, 95% CI 1.44–3.66, <i>p</i> &lt; 0.001), NAC (neoadjuvant chemotherapy) regimens (HR = 0.56, 95% CI 0.35–0.90, <i>p</i> = 0.017), and MK_Group (HR = 0.52, 95% CI 0.33–0.82, <i>p</i> = 0.003) as independent prognostic factors. The MK_Group high exhibited superior survival rates versus MK_Group low (2-year: 94% vs. 81%; 5-year: 85% vs. 66%; 10-year: 79% vs. 64%; all <i>p</i> &lt; 0.05). The nomogram combining Clinical Stage, NAC, and MK_Group demonstrated moderate predictive accuracy for 2-, 5-, and 10-year PFS (AUC = 0.736, 0.718, 0.697).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Pretreatment MK serves as a robust noninvasive biomarker for long-term PFS in NPC. Integration with Clinical Stage and NAC regimens enhances prognostic stratification, supporting personalized therapeutic strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 9","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70883","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal Primary Prophylaxis for Febrile Neutropenia During Neoadjuvant Cisplatin and 5-Fluorouracil Plus Docetaxel for Esophageal Cancer: A Retrospective Cohort Study","authors":"Ryosuke Kumanishi,&nbsp;Hiroya Taniguchi,&nbsp;Taiko Nakazawa,&nbsp;Takatsugu Ogata,&nbsp;Yuki Matsubara,&nbsp;Hiroyuki Kodama,&nbsp;Akinobu Nakata,&nbsp;Kazunori Honda,&nbsp;Toshiki Masuishi,&nbsp;Yukiya Narita,&nbsp;Shigenori Kadowaki,&nbsp;Masashi Ando,&nbsp;Masahiro Tajika,&nbsp;Tetsuya Abe,&nbsp;Kei Muro","doi":"10.1002/cam4.70889","DOIUrl":"https://doi.org/10.1002/cam4.70889","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Neoadjuvant chemotherapy (NAC) with docetaxel, cisplatin, and 5-fluorouracil (5-FU) (DCF) is the standard treatment for locally advanced esophageal cancer (LAEC). DCF is associated with a high risk of febrile neutropenia (FN), but the optimal primary prophylaxis remains unclear. The present study aimed to assess risk factors for FN and efficacy of primary prophylaxis using granulocyte colony-stimulating factor (G-CSF) and antibiotics in LAEC patients treated with DCF.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with LAEC who received DCF as NAC between January 2016 and June 2022 at Aichi Cancer Center Hospital were retrospectively analyzed. DCF consisted of docetaxel 70 mg/m² on day 1, cisplatin 70 mg/m² on day 1, and 5-FU 750 mg/m² by continuous infusion over 5 days. The patients were divided into Cohort A [no G-CSF], B1 (G-CSF after day 6), and B2 (G-CSFon day 3–4). The efficacy of primary prophylaxis with G-CSF and antibiotics during the first cycle was evaluated. The potential FN risk factors were evaluated using univariate and multivariate analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the 156 patients with esophageal cancer who received DCF as NAC, 41 (26%) patients developed FN during the first cycle. Multivariate analysis revealed that prophylactic antibiotics (17% vs. 40%; adjusted OR, 0.34; 95% confidence interval [CI], 0.16–0.73; <i>p</i> = 0.006) and G-CSF (6% vs. 35%; adjusted OR, 0.14; 95% CI, 0.04–0.47; <i>p</i> = 0.002) were associated with lower FN incidence. The grade 3/4 neutropenia rates were 84%, 43%, and 13% in cohorts A, B1, and B2, respectively. FN incidence was 35%, 13%, and 0% in the respective cohorts. Treatment-related death occurred in 2% of patients, none of whom received G-CSF prophylaxis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Prophylactic G-CSF and antibiotics reduce the risk of FN in patients with LAEC treated with DCF. Early timing of G-CSF administration showed a potential trend toward reduced FN risk and may offer additional benefits; however, these findings must be validated.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 9","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70889","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}